<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20120615152900+02'00'</creation_date><modification_date>D:20120615152900+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-129_h_dec_10.pdf</pdf_file></head><body><section><header>european commission brussels, 15.6.2012 c(2012)4211 final</header></section><section><header>commission implementing decision of 15.6.2012 
 amending the marketing authorisation granted by decision c(2000)576 for “azopt - 
 brinzolamide”, a medicinal product for human use</header><p>(text with eea relevance) (only the english text is authentic)</p></section><section><header>commission implementing decision of 15.6.2012 
 amending the marketing authorisation granted by decision c(2000)576 for “azopt - 
 brinzolamide”, a medicinal product for human use</header><p>(text with eea relevance) (only the english text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to the notification submitted by alcon laboratories (uk) ltd., under the 
 first and the second subparagraph of article 14(1) of regulation (ec) no 1234/2008, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the minor variations of 
 type ia, notified between 8 february 2012 and 2 may 2012, and of the need to 
 amend the decision granting the marketing authorisation. 
 (2)</p><p>the marketing authorisation should be updated and decision c(2000)576 of 9 
 march 2000 should therefore be amended accordingly. the community register 
 of medicinal products should also be updated.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p><p> (3) for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2000)576 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2000)576 is amended as follows: 1) the following notifications for minor variations are added to the marketing 
 authorisation: 
 application number 
 scope (eu numbers affected)</p><p>emea/h/c/267/ig/149/g 
 c.i.9.a), c.i.9.h) (eu/1/00/129/001-003)</p><p>
 2) annex ii is replaced by the text set out in the annex ii to this decision. 
 article 2 this decision is addressed to alcon laboratories (uk) ltd., pentagon park, boundary way, hemel hempstead, herts hp2 7ud, united kingdom. 
 done at brussels, on 15.6.2012.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>